Clinical Trials Directory

Trials / Completed

CompletedNCT00048802

Treatment and Outcome of Early Onset Bipolar Disorder

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
40 (planned)
Sponsor
Northwell Health · Academic / Other
Sex
All
Age
10 Years – 18 Years
Healthy volunteers
Not accepted

Summary

This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder.

Detailed description

In children and adolescents, bipolar disorder is often accompanied by symptoms such as hallucinations, delusions, or paranoia that require acute treatment with a combination of an atypical antipsychotic medication and a mood stabilizer. It is not known if it is necessary to continue treatment with the atypical antipsychotic medication after the child's symptoms have remitted. Participants in this study are treated with lithium, divalproex (Depakote), and one of the following atypical antipsychotic medications: olanzapine (Zyprexa), risperidone (Risperdal) or quetiapine (Seroquel) for at least 24 weeks. Participants who have already begun combination therapy with at least one of the mood stabilizers and atypical antipsychotic medications listed above are also encouraged to enroll in this study. After participants have been on combination therapy for at least 24 weeks they will then be randomly assigned to one of two groups. The first group will continue to receive active mood stabilizer and atypical antipsychotic medication. The second group will receive active mood stabilizer and placebo. Participants are assessed weekly and followed for up to 18 months.

Conditions

Interventions

TypeNameDescription
DRUGLithium
DRUGOlanzapine
DRUGDivalproex
DRUGRisperidone
DRUGQuetiapine
DRUGZiprasidone
DRUGAripriprazole

Timeline

Start date
2002-08-01
Primary completion
2006-08-01
Completion
2006-08-01
First posted
2002-11-13
Last updated
2014-01-22

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00048802. Inclusion in this directory is not an endorsement.